Leader in anthracycline drug design for over 50 years.
Co-Founder/Board Chairman, Anthra Pharmaceuticals, Inc. Discoverer of Valstar®, FDA-approved agent for human bladder cancer.
4 U.S. and international patents for novel anthracycline agents.
NIH-funded Professor of Pharmacology, UTHSC.
Over 350 publications in drug development.
Former faculty and Assoc. Chief for Drug Development at the Dana-Farber Cancer Institute/Harvard Med School.

Professor of Cardiovascular Disease at UTHSC.
Adjunct faculty, Biomedical Engineering, Univ. of Memphis.
Over 35 years of clinical/research experience in arrhythmias, heart failure.
PI or Primary Cardiovascular Consultant on numerous multicenter clinical trials.
Fellow, Heart Rhythm Society and American College of Cardiology.
NIDDK-funded researcher in preventative cardiology studies.
Funded researcher, antitumor drug cardioprotection.

Professor of Pharmacology, UTHSC.
Over 35 years in qualitative/quantitative drug analysis, pharmacokinetics, cancer drug development.
Extensive track record of publication and NIH funding in development, preclinical and clinical testing of novel anthracyclines.
Former Associate Editor of Clinical Cancer Research.
Representative to the United States Pharmacopeia Convention.
Consultant in Pharmacology, Huntington Medical Research Institute.

Professor of Medicinal Chemistry, Univ. of MS College of Pharmacy.
Research Professor, Research Institute of Pharmaceutical Sciences.
Over 65 papers and multiple patents in synthetic medicinal chemistry, drug design, bioorganic chemistry and environmental toxicology.
Assoc. Editor, Journal of Medicinal Chemistry Letters.
Research funding from NIH, CDC, USDA, NOAA, AHA and AACP.
President of the MALTO Medicinal Chemistry organization.